Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 288,865 shares, a decline of 22.7% from the February 26th total of 373,692 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 210,084 shares, the days-to-cover ratio is currently 1.4 days.

Jyong Biotech Trading Down 4.0%

Jyong Biotech stock opened at $1.94 on Friday. The business's 50-day simple moving average is $2.21 and its 200-day simple moving average is $23.02. Jyong Biotech has a 52 week low of $1.43 and a 52 week high of $67.00.

Jyong Biotech (NASDAQ:MENS - Get Free Report) last released its earnings results on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Trading of Jyong Biotech

A number of hedge funds have recently bought and sold shares of MENS. BNP Paribas Financial Markets acquired a new stake in Jyong Biotech in the 3rd quarter worth $67,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech in the fourth quarter valued at about $49,000. Millennium Management LLC acquired a new stake in Jyong Biotech during the third quarter worth about $512,000. Man Group plc bought a new position in Jyong Biotech during the fourth quarter valued at about $56,000. Finally, Geode Capital Management LLC grew its holdings in shares of Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company's stock worth $254,000 after purchasing an additional 10,538 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of "Sell".

Check Out Our Latest Stock Report on MENS

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

Read More

• Five stocks we like better than Jyong Biotech

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jyong Biotech Right Now?

Before you consider Jyong Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.

While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here